Well reported studies of labelling issues give unfair bad press to CBD – but it is an issue the industry urgently needs to address, according to speakers at the Food and Drug Law Institute’s annual conference ...
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.
Regulatory report: medical and recreational cannabis – a global overview
CBD-Intel has compiled and classified the regulatory data on medical and recreational cannabis in 50 jurisdictions around the world.
The report, accompanied by a more detailed database, provides an overview of the regulatory situation in the selected countries using maps, and assesses the likelihood that the status quo may change in the future.